Pham Quang X sold $93K of CVKD
Pham Quang X (Chairman, CEO and Interim CFO) sold 22,385 shares of Cadrenal Therapeutics, Inc. (CVKD) at an average of $4.17 ($4.06–$4.38) across 3 trades over 2026-06-08 to 2026-06-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO/Chairman/10% owner’s open-market sale totaling 22,385 shares ($93,293.86) executed over three days under a 10b5-1 plan.
Market read
This is a routine insider-sale filing; it may slightly affect sentiment but is unlikely to be a standalone fundamental catalyst.
What to watch
Traders may overreact to insider sales; the key is whether CVKD has concurrent catalysts (financing, trial updates, partnerships) not present in this article.
Background
The article is an SEC Form 4 insider transaction disclosure for Cadrenal Therapeutics, Inc.
Ticker impact
Cadrenal Therapeutics CEO/Chairman/10% owner Pham Quang X sold $93.3K of CVKD shares via an open-market sale under a 10b5-1 plan.
Near-term sentiment drag is possible, but magnitude is likely limited given the relatively small $93K value versus typical microcap float.
The filing is a primary-source Form 4 showing multiple-day sales ($4.06–$4.38) by a top insider; however, the presence of a pre-arranged 10b5-1 plan reduces interpretive weight.
Market effects
No direct sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sales were executed under a pre-arranged 10b5-1 plan, the disclosure may reflect routine liquidity rather than bearish fundamentals.
Key entities
- issuerCadrenal Therapeutics, Inc.
Company whose insider transaction is disclosed on SEC Form 4.
- insiderPham Quang X
Chairman, CEO, Interim CFO; officer/director/10% owner who sold CVKD shares.
